Atriva Therapeutics Coöperatie U.A.

INTRODUCTION Meneldor offers her customers the unique opportunity to co-invest alongside specialists, in exciting early stage Biotech and Pharma companies. A sector often considered as very risky and highly complex. Meneldor thoroughly studies the science behind her potential portfolio companies. If the science is sound, then all other key aspects; IP, medical need, addressable markets, competition, risk, management, financial needs, valuation, etc., are assessed. Only if a target company meets our selection criteria, Meneldor will invest and invite her co-investors to participate. INVESTMENT FOCUS Meneldor focuses on early stage biotech and pharma companies that (re)develop (New) Bio or Chemical Molecular Entities or Repurposed drugs, that have outstanding technology with strong IP, address significant unmet medical needs and attractive markets. We are especially scouting for companies that work on relatively low risk and high growth opportunities. We mainly invest in projects which are in preclinical, Phase I or early Phase II and in indications with preferably clear well defined clinical endpoints. Our geographic focus is Europe. CURRENT HOLDINGS AND PIPELINE Meneldor has a very exciting pipeline. Details will be shared only under NDA. Our current holdings are: 2016: Xenikos B.V. (Netherlands) 2017: Atriva Therapeutics GmbH (Germany) 2018: Aptamer Group Ltd (UK) 2019: LightOx Ltd (UK) 2021: TagWorks Pharma (Netherlands) 2022: Hemispherian (Norway)